Liver membrane composition after short-term parenteral nutrition with and without taurine in guinea pigs: the effect to taurine.
Having recently demonstrated that taurine supplementation prevents total parenteral nutrition (TPN)-induced cholestasis, we chose to use this model to examine plasma membrane composition in relation to bile formation. Male guinea pigs received daily a mixture of glucose and of the amino acid solution Travasol with or without added taurine (1.2 mM). After 3 days, bile was collected and liver plasma membrane fractions enriched in sinusoidal lateral membrane and bile canalicular membrane domains were isolated. In animals receiving TPN alone, bile flow and biliary secretory rate of bile acid and bicarbonate decreased significantly compared with controls. Although membrane ATPases (Na+K+ and Mg+) were unchanged, TPN induced an increase in the lipid to protein ratio and a decrease of polyunsaturated fatty acids, in conjunction with a higher content of diene conjugates in sinusoidal lateral membrane fractions. Taurine corrected these changes and, in addition, reduced significantly the cholesterol to phospholipid ratio in both membrane fractions. The data show that changes in liver cell membranes occur in TPN-induced cholestasis and suggest that free radical injury may play a role. As taurine prevented cholestasis as well as membrane changes, it is suggested that taurine should be added to amino acid solutions used for parenteral nutrition.
Guertin
F
F
Department of Nutrition, University of Montreal, Québec, Canada.
Roy
C C
CC
Lepage
G
G
Yousef
I
I
Tuchweber
B
B
D000596:Amino Acids / Q000008:administration & dosage; D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D001646:Bile / Q000187:drug effects / Q000502:physiology; D001647:Bile Acids and Salts / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D004573:Electrolytes; D005947:Glucose / Q000008:administration & dosage; D006168:Guinea Pigs; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure*; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism; D010288:Parenteral Nutrition; D057947:Parenteral Nutrition Solutions; D010743:Phospholipids / Q000378:metabolism; D012996:Solutions; D013654:Taurine / Q000187:drug effects / Q000494:pharmacology*
D000596:Amino Acids; D001639:Bicarbonates; D001647:Bile Acids and Salts; D004573:Electrolytes; D008563:Membrane Lipids; D008565:Membrane Proteins; D057947:Parenteral Nutrition Solutions; D010743:Phospholipids; D012996:Solutions; C545824:amino-acid, glucose, and electrolyte solution; D013654:Taurine; D002784:Cholesterol; D005947:Glucose